Aardvark Therapeutics, Inc. (AARD)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$1.11-11.90%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
QuarterlyIQ Insights · AARD
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -63.7% |
| Our one-year growth estimate | diamond | -69.6% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 5.8 percentage points more one-year growth.
The one-year revenue growth assumption on Valuation.
Worth watching into the next print: this name is a smaller-cap name (higher miss base rate) and operates in a high-miss-rate industry. A fundamental tilt, not a price call.
Model as of 2026-11-04 · Compared with 66 industry peers
AARD — CIO transition
Dated 2026-10-08
Director — David (Zhongwei) Zhang: The filing discloses the appointment of a new independent director to the board, which is a routine governance event and not the departure of a senior executive.
Why it matters: A cardiac event could delay ARD-101 trials again. The FDA linked one serious event to a drug interaction with pitolisant.
Worry ifA new trial report or filing reports a serious heart event linked to ARD-101 or a drug interaction.
Less concerning ifThe resumed trial reports no cardiac events and no new heart-related pause.
Why it matters: Aardvark reported $73.9 million in cash and investments at June 30, 2026. The next earnings update can show whether spending keeps the late-2027 runway intact.
Worry ifThe November 12, 2026 earnings update keeps the runway into late 2027 and reports cash above $73.9 million.
Less concerning ifThe update cuts the runway to before late 2027 or reports cash below $73.9 million.
Why it matters: The terminated HERO trial had only 67 of 90 planned participants. Its results are exploratory, so a new trial must test whether hunger scores improve.
Supportive ifThe new Phase 3 trial meets its stated main HQ-CT goal and reports a clear benefit over placebo.
Worry ifThe new Phase 3 trial misses its main HQ-CT goal or shows no benefit over placebo.
Why it matters: FDA agreement would clear a key step toward restarting the PWS study. The old trial data cannot prove that the drug works.
Supportive ifAardvark reports an FDA meeting and a new Phase 3 plan, with no added study required before restart.
Worry ifThe FDA asks for more studies or does not align on the Phase 3 plan.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$491 on $10,000 · ±4.9% | How much price usually moves either way. |
| Bad day | $1,070 loss on $10,000 · 10.7% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $9,317 loss on $10,000 · 93.2% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: A restart would show that the FDA and company have a path past the prior safety hold. The prior serious heart event involved 800 mg twice daily and another drug.
Supportive ifAardvark reports that PWS patients have restarted ARD-101 below 800 mg twice daily.
Worry ifDosing has not restarted by the end of 2027, or a new heart safety issue delays the study.